SPRO Spero Therapeutics Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company is headquartered in Cambridge, Massachusetts.

Date	Price Target	Rating	Analyst
12/20/2024	$5.00	Outperform → In-line	Evercore ISI
9/23/2022	$2.00 → $8.00	In-line → Outperform	Evercore ISI
10/1/2021		Outperform → Perform	Oppenheimer

Spero Therapeutics Inc.

Peers

Recent Analyst Ratings for Spero Therapeutics Inc.

Spero Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mahadevia Ankit was granted 20,000 shares, increasing direct ownership by 3% to 709,866 units (SEC Form 4)

Director Deshpande Milind was granted 20,000 shares, increasing direct ownership by 28% to 91,454 units (SEC Form 4)

Director Jackson Scott Thomas was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

Director Vink Patrick V.J.J. was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

Director Pottage John C Jr was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

Director Smith Cynthia was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

Director Thomas Frank E was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

Director Tregoning Kathleen was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

Officer Rajavelu Esther was granted 185,000 shares, increasing direct ownership by 26% to 909,720 units (SEC Form 4)

Chief Operating Officer Keutzer Timothy was granted 266,139 shares and sold $44,099 worth of shares (56,537 units at $0.78), increasing direct ownership by 39% to 741,439 units (SEC Form 4)